Uterine Cancer Surgery

Free consultation

Find out whether your case suits keyhole surgery

The review costs nothing and commits you to nothing. Send the endometrial biopsy or curettage report with the tumor grade and type, the pelvic MRI and any CT with the actual images, and a note of your height, weight and other medical conditions. A gynecologic oncologist will tell you which approach fits your case, whether sentinel node mapping applies, and what the operation would involve.

What the operation involves

Cancer of the uterus, meaning cancer arising in the endometrial lining, gets treated first with surgery in the overwhelming majority of cases. The standard operation removes the uterus and the cervix together, along with both fallopian tubes and both ovaries, and it samples or maps the pelvic lymph nodes where the tumor grade and depth of invasion justify it. Washings from the abdominal cavity go to the laboratory alongside the specimen. For a woman with early, low-grade disease, that single operation is often the entire cancer treatment, with nothing to follow except surveillance appointments.

Cure rates in that group sit among the highest in oncology.

Two things separate this operation from a hysterectomy done for fibroids or heavy bleeding, and both matter when choosing where to have it. The specimen has to come out intact, without the uterus being cut up inside the abdomen, because morcellating a cancer scatters it. And the surgeon has to be prepared to stage the disease properly in the same sitting, which means knowing when to take nodes, when to sample the omentum, and how to read the frozen section if the unit uses one. A general gynecologist can perform a technically clean hysterectomy and still leave a cancer under-staged, which changes what treatment follows and how well it works.

Keyhole or open, and the trial that confuses people

Keyhole surgery for uterine cancer, whether performed laparoscopically or with a robot, is the standard approach across Europe, North America and Turkey, and the evidence behind it is a randomized trial rather than a marketing claim.

The trial in cancer of the uterus

According to PubMed, 760 women with stage I endometrioid uterine cancer were randomly assigned to total laparoscopic or total abdominal hysterectomy across 20 gynecological cancer centers. At four and a half years, disease-free survival stood at 81.6 percent in the laparoscopic group and 81.3 percent in the open group, a difference of 0.3 percentage points that met the trial's criterion for equivalence, with recurrence occurring in 8.1 percent and 7.9 percent respectively (Janda et al, 2017). Smaller incisions, less blood loss and a shorter stay came without a cancer penalty.

The trial in cancer of the cervix

A second trial then changed the conversation, and the confusion it created still reaches consultation rooms. PubMed indexes a study of 631 women with early cervical cancer, randomly assigned to minimally invasive or open radical hysterectomy, in which disease-free survival at four and a half years reached 86.0 percent with the keyhole approach and 96.5 percent with the open one, a gap of 10.6 percentage points. The hazard ratio for recurrence or death from cervical cancer was 3.74, and three-year overall survival came out at 93.8 percent against 99.0 percent (Ramirez et al, 2018). Practice for cervical cancer reversed within months.

This table scrolls sideways on a narrow screen. Swipe or drag to see every column.

Patients who have read about the cervical result frequently arrive asking for open surgery on a uterine cancer, and the request deserves a proper answer instead of reassurance. The likely explanations for the cervical finding are specific to that operation, chiefly the use of a manipulator inside the vagina and the opening of the tumor-bearing tissue into the abdominal cavity during a radical dissection, neither of which forms any part of a standard hysterectomy performed for cancer of the uterus. Evidence for one organ does not transfer to the other. The trials are not interchangeable.

Open surgery still has its place here. A very large uterus that could not be removed intact through the vagina, dense adhesions from earlier operations, advanced disease that needs a wider clearance, or a chest that will not tolerate the head-down position required for laparoscopy all point toward a conventional incision. The choice belongs to the surgeon who has seen your imaging.

Sentinel nodes and the three percent

Knowing whether cancer has reached the lymph nodes changes what treatment follows, and for many years the only way to know involved stripping out the pelvic node chains, an operation that leaves a proportion of women with permanent leg swelling. Sentinel mapping replaced it. A green fluorescent dye goes into the cervix at the start of the operation, travels the same lymphatic channels the tumor would use, and lights up the first node on each side, which the surgeon removes and sends for detailed examination. According to PubMed, 385 women having robotic staging received the dye and then went on to full lymphadenectomy so the two methods could be compared directly. At least one sentinel node was found in 86 percent of them. Among the women who did have cancer in their nodes and whose mapping succeeded, the sentinel node identified the disease in 35 of 36 cases, giving a sensitivity of 97.2 percent and a negative predictive value of 99.6 percent (Rossi et al, 2017).

Where the dye fails to map one side of the pelvis, the standard response is to remove the nodes on that side in the conventional way. Establish what the unit does in that situation.

The report that decides everything after

Surgery removes the cancer. The pathology report decides what happens next, and for uterine cancer that report has changed more in the last decade than the operation has. Alongside the familiar findings of grade, how deeply the tumor invaded the muscle wall, whether it reached the cervix and whether lymphatic channels were involved, laboratories now classify the tumor into one of four molecular groups. Those groups separate outcomes far more sharply than grade alone ever did.

This table scrolls sideways on a narrow screen. Swipe or drag to see every column.

For anyone traveling for surgery, this has a practical edge. Establish before the operation whether the laboratory performs molecular classification and whether the result appears in the final report, because a report without it leaves your own oncologist making an adjuvant decision on incomplete information, and repeating the testing at home means tracking down tissue blocks held in another country by a laboratory that has no obligation to release them quickly. The immunohistochemistry itself is inexpensive and widely available. Arranging for it to reach the report you carry home is the part people forget.

Weight, and why it matters here

Uterine cancer carries a stronger link with body weight than almost any other tumor, so a large share of the women having this operation are carrying substantial excess weight, and pretending otherwise helps nobody. Open surgery in that setting brings a markedly higher rate of wound infection and wound breakdown, along with a longer stay and a slower return to walking, while the keyhole approach avoids the long incision altogether and the robotic platform holds a further advantage where the abdominal wall is thick, because the instruments hold their position without the surgeon fighting the leverage of a long lever through a deep wall. The gap is wide.

So the women who benefit most from keyhole surgery are frequently the ones a surgeon might hesitate to attempt it on.

Two limits are real, and they deserve discussion instead of reassurance.

• Laparoscopy needs the patient positioned steeply head-down for a prolonged period, which loads the lungs and the heart, so anesthetic assessment carries more weight than usual and occasionally rules the approach out.
• A proportion of laparoscopic operations convert to open surgery partway through, which is a judgment made for safety and belongs in the consent conversation as a possibility rather than a failure.

Request the unit's own conversion rate for patients of similar build.

Keeping the uterus, and who can

Some younger women with uterine cancer want to carry a pregnancy, and for a narrow set of them the uterus can stay, at least for a while. The criteria are strict. Grade 1 endometrioid cancer, no invasion of the muscle wall on a good-quality MRI, no evidence of disease outside the uterus, and a woman who accepts close surveillance and a hysterectomy once childbearing finishes or the treatment fails.

Treatment in that setting means progestin, given by tablet or by a hormone-releasing coil, with repeat sampling of the lining every three to six months to confirm the cancer has cleared. Fertility treatment usually follows, since conception rates without help are low in this group.

Anyone considering this route needs a gynecologic oncologist and a fertility specialist in the same conversation, and needs to hear plainly that the approach trades a small increase in risk for the chance of a pregnancy. Women outside those criteria are not candidates, and a clinic willing to offer it without the MRI and the grading in hand is offering something other than cancer care.

Theater day and the first nights

Keyhole hysterectomy for cancer follows the same sequence in almost every unit, and knowing it in advance removes most of the fear attached to the day.

Blood loss in a keyhole operation stays modest enough that transfusion rarely arises, though a bulky uterus or dense adhesions from earlier surgery lengthen the operation and raise it. One or two nights on the ward covers most keyhole cases. An open operation runs to four or five.

What can go wrong

Serious complications stay uncommon after keyhole surgery for uterine cancer. This operation sits at the safer end of cancer surgery without being trivial, and injury to the bladder, the ureter or the bowel happens in a small minority of cases, recognized and repaired during the same operation in most of them, while bleeding needing transfusion, infection of the vaginal vault and a collection in the pelvis make up most of what remains. Three further problems deserve naming, because women meet them after discharge and do not expect them.

• Vaginal vault dehiscence, where the top of the vagina opens. It is rare, it needs emergency attention, and it is the reason nothing goes into the vagina for six weeks.
• Leg swelling from lymphedema, which follows node removal and is much less common since sentinel mapping replaced full clearance, though it still occurs.
• Clots in the leg or lung, which remain a risk after any pelvic cancer surgery, so the blood-thinning injections continue for a period after you leave hospital.

Removing the ovaries brings on the menopause immediately in a woman still short of it. Hot flushes and disturbed sleep start within days, and whether hormone replacement can follow depends on the tumor type and on your oncologist's assessment of your case, which is a conversation to have at the consultation while there is still time to plan around the answer.

Recovery, week by week

Recovery after keyhole surgery runs considerably faster than after an open operation, and the difference shows within the first fortnight. Through the first week the port sites ache, tiredness dominates, and short walks several times a day beat one long attempt. By the second and third week most women manage stairs, light housework and driving once an emergency stop would not make them flinch, though anyone still taking strong painkillers should stay out of the car. Lifting stays restricted for six weeks, nothing enters the vagina for the same six weeks while the vault heals, which covers intercourse, tampons and swimming alike, and light bleeding or brownish discharge across that period is expected rather than alarming. Office work resumes somewhere between four and six weeks. After an open operation the same milestone falls closer to eight or ten.

What needs a call the same day

Either of two developments needs a call the same day. Heavy fresh bleeding from the vagina, and a leg that swells or aches on one side, both need assessment the same day wherever you happen to be.

Traveling for the operation

Ten to fourteen days in the country covers a keyhole case comfortably, with two or three days at the front going to imaging review, blood tests, anesthetic assessment and the consultation itself, one to two nights for the admission, and the remainder left for wound review and a fitness-to-fly check before departure. An open operation stretches the plan to three weeks. Book the return flight loosely and confirm it once the surgical team clears you, since a fixed date bought in advance turns any small delay into an expensive one. One timing problem catches almost everyone. The final pathology, and the molecular classification if it is being done, takes one to three weeks to issue, so the report that determines whether you need radiotherapy or chemotherapy will land after you fly home. Waiting in the country for it wastes weeks. Arranging in advance for it to be sent directly to your own oncologist, in a language they read, costs nothing and saves the delay.

Bringing a companion makes the trip easier, and the first days at home afterward easier still, though this operation does not demand one in the way an open cancer clearance does. A companion bed sits in the room if someone does travel with you. Ask for the histopathology report in English and ask how many working days it takes, since that date, rather than the surgery, is usually what decides how long you stay.

What drives the cost

Four things move the figure more than anything else. Whether the operation is laparoscopic, robotic or open, since the robotic platform carries consumable costs per case that the others do not. Whether sentinel node mapping is performed, which adds the fluorescent dye and the imaging system. How many nights the admission runs, which the approach largely determines. And how extensive the pathology is, since molecular classification, immunohistochemistry and examination of multiple nodes cost more than a simple specimen report. Patient factors move it too, particularly weight, previous abdominal surgery and other medical conditions that lengthen the anesthetic assessment. Published packages in this market ordinarily cover surgeon and anesthesiologist fees, theater time, a defined number of nights, pre-operative imaging and blood work, standard histopathology, and transfers with interpreting, while flights, accommodation beyond the stated nights, treatment of a complication, radiotherapy or chemotherapy afterward, and sometimes the molecular testing itself sit outside them.

That last exclusion is the one to check.

Before accepting a quote, establish whether robotic assistance changes the figure and by how much, whether sentinel mapping is included, whether the quote covers full pathology with molecular classification or only the basic report, and what an extra night costs if the surgeon converts to an open operation. A surgeon who has reviewed your imaging and your biopsy can answer all of it, and that review costs nothing.

Back home, and the follow-up

Five things travel home with you, and a missing one costs weeks.

1. The operative note, recording what was removed and by which approach.
2. The full histopathology report, with stage, grade, depth of invasion, lymphovascular invasion and node status.
3. The molecular classification, where the laboratory performed it.
4. A copy of the imaging on a disc or a drive, with the actual image files.
5. A written statement of what the treating team recommends next, since a recommendation from the surgeons who saw the disease carries weight with an oncologist who did not.

Once you are home, follow-up runs on examination for most women, with clinical review every three to six months through the first two years, tapering after that, and imaging arranged only when symptoms or an examination finding raise a question. Scans on a fixed schedule add little here. Any bleeding from the vagina after treatment needs reporting the same week.

Remote follow-up with the operating surgeon has a specific value in the first months, because the person who was in theater can interpret an unexpected finding on a scan reported near where you live far more usefully than someone reading it cold. Agree how that contact works before you leave.

Frequently asked questions